Share Price and Basic Stock Data
Last Updated: September 3, 2024, 11:03 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Ortin Laboratories Ltd operates within the pharmaceuticals sector, with a current market capitalization of ₹16.4 Cr and a share price of ₹20.1. The company has experienced significant fluctuations in revenue over the years. Sales reported for the fiscal year ending March 2024 stood at ₹2.28 Cr, a stark decline from ₹8.16 Cr in March 2021 and ₹8.23 Cr in March 2022. Quarterly sales have also shown volatility, peaking at ₹2.62 Cr in June 2022 before falling to just ₹0.14 Cr in December 2023. This downward trend highlights challenges in maintaining consistent revenue generation. The operating profit margin has been particularly concerning, with a reported figure of -1,016.67% for March 2024, indicating severe operational inefficiencies. In summary, the revenue trajectory of Ortin Laboratories reflects significant instability, raising questions about the sustainability of its business model.
Profitability and Efficiency Metrics
Profitability metrics for Ortin Laboratories Ltd indicate a troubling scenario. The company reported a net profit of -₹8.04 Cr for the fiscal year ending March 2024, compared to a net profit of ₹0.95 Cr in March 2021. This decline in profitability is further underscored by the negative earnings per share (EPS), which stood at -₹9.89 for March 2024, down from ₹1.17 in March 2021. The operating profit has also deteriorated, with a recorded operating profit of -₹6.37 Cr for the fiscal year ending March 2024, reflecting operational inefficiencies. Return on equity (ROE) is reported at 118%, which initially appears strong; however, it raises concerns due to the negative net profit. The interest coverage ratio (ICR) stands at 3.63x, indicating that the company can cover its interest obligations, but the overall profitability metrics suggest systemic issues that need addressing.
Balance Sheet Strength and Financial Ratios
The balance sheet of Ortin Laboratories shows a precarious financial position. As of March 2024, the company reported reserves of -₹5.31 Cr, contrasting sharply with previous years where reserves were positive. Borrowings have decreased to ₹1.80 Cr, down from ₹6.94 Cr in March 2021, reflecting a reduction in debt but also potentially limiting operational flexibility. The price-to-book value ratio stands at 1.97x, indicating that investors are willing to pay nearly double the book value for the stock. However, the negative reserves raise red flags about the company’s financial health. Additionally, the total liabilities have significantly decreased to ₹6.59 Cr as of March 2024, but this is coupled with a substantial decline in total assets to the same amount, indicating a possible asset write-down or liquidation of assets. The financial ratios suggest that while there is some debt management, the overall balance sheet remains vulnerable.
Shareholding Pattern and Investor Confidence
Information regarding the shareholding pattern of Ortin Laboratories is incomplete, with data on promoters, foreign institutional investors (FIIs), domestic institutional investors (DIIs), and public shareholders not available. This lack of transparency can lead to investor uncertainty, especially in light of the company’s poor financial performance. The absence of promoter stake information raises concerns about the commitment of insiders to the company’s future. The reported market capitalization of ₹16.4 Cr and the price-to-earnings (P/E) ratio remain unspecified, which complicates the assessment of investor confidence. Given the declining revenue and profitability metrics, potential investors may exercise caution. The company’s struggles may deter institutional investors, while retail investors might also hesitate to invest without clearer insights into the management and strategic direction.
Outlook, Risks, and Final Insight
The outlook for Ortin Laboratories appears challenging given the current financial landscape. The significant drop in revenue and persistent net losses highlight the operational difficulties faced by the company. Risks include ongoing operational inefficiencies, potential liquidity issues due to negative reserves, and lack of investor confidence stemming from an opaque shareholding structure. Without strategic interventions to stabilize operations and restore profitability, the company’s future remains uncertain. The potential for recovery hinges on management’s ability to implement effective strategies to enhance revenue generation and operational efficiency. Should the company manage to turn around its financial performance, it could regain investor interest. Conversely, continued deterioration may lead to further loss of market confidence and possibly jeopardize its future viability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Ortin Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 137 Cr. | 109 | 247/84.3 | 31.1 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,906 Cr. | 450 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 36.9 Cr. | 25.2 | 29.1/17.0 | 38.5 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,608.79 Cr | 1,177.38 | 55.81 | 198.49 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.76 | 1.98 | 2.29 | 1.66 | 2.45 | 2.62 | 0.79 | 1.17 | 1.49 | 1.57 | 0.27 | 0.14 | 0.30 |
| Expenses | 1.55 | 1.61 | 2.00 | 1.65 | 2.59 | 2.41 | 1.01 | 0.55 | 1.52 | 1.39 | 1.17 | 2.74 | 3.35 |
| Operating Profit | 0.21 | 0.37 | 0.29 | 0.01 | -0.14 | 0.21 | -0.22 | 0.62 | -0.03 | 0.18 | -0.90 | -2.60 | -3.05 |
| OPM % | 11.93% | 18.69% | 12.66% | 0.60% | -5.71% | 8.02% | -27.85% | 52.99% | -2.01% | 11.46% | -333.33% | -1,857.14% | -1,016.67% |
| Other Income | 0.05 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.19 | 0.18 | 0.19 | 0.19 | 0.24 | 0.10 | 0.09 | 0.10 | 0.12 | 0.11 | 0.15 | 0.14 | 0.08 |
| Depreciation | 0.07 | 0.07 | 0.07 | -0.07 | 0.23 | 0.07 | 0.07 | 0.07 | 0.03 | 0.06 | 0.06 | 0.06 | 0.05 |
| Profit before tax | 0.00 | 0.12 | 0.07 | -0.11 | -0.61 | 0.04 | -0.38 | 0.45 | -0.21 | 0.01 | -1.11 | -2.80 | -3.18 |
| Tax % | 25.00% | 28.57% | -18.18% | -24.59% | 1,150.00% | -121.05% | 0.00% | -4.76% | 0.00% | 1.80% | -0.71% | 30.19% | |
| Net Profit | 0.80 | 0.09 | 0.05 | -0.09 | -0.45 | -0.43 | 0.08 | 0.46 | -0.20 | 0.02 | -1.12 | -2.79 | -4.14 |
| EPS in Rs | 0.98 | 0.11 | 0.06 | -0.11 | -0.55 | -0.53 | 0.10 | 0.57 | -0.25 | 0.02 | -1.38 | -3.43 | -5.09 |
Last Updated: Unknown
Below is a detailed analysis of the quarterly data for Ortin Laboratories Ltd based on the most recent figures (Mar 2024) and their trends compared to the previous period:
- For Sales, as of Mar 2024, the value is 0.30 Cr.. The value appears strong and on an upward trend. It has increased from 0.14 Cr. (Dec 2023) to 0.30 Cr., marking an increase of 0.16 Cr..
- For Expenses, as of Mar 2024, the value is 3.35 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.74 Cr. (Dec 2023) to 3.35 Cr., marking an increase of 0.61 Cr..
- For Operating Profit, as of Mar 2024, the value is -3.05 Cr.. The value appears to be declining and may need further review. It has decreased from -2.60 Cr. (Dec 2023) to -3.05 Cr., marking a decrease of 0.45 Cr..
- For OPM %, as of Mar 2024, the value is -1,016.67%. The value appears strong and on an upward trend. It has increased from -1,857.14% (Dec 2023) to -1,016.67%, marking an increase of 840.47%.
- For Other Income, as of Mar 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2023) which recorded 0.00 Cr..
- For Interest, as of Mar 2024, the value is 0.08 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.14 Cr. (Dec 2023) to 0.08 Cr., marking a decrease of 0.06 Cr..
- For Depreciation, as of Mar 2024, the value is 0.05 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.06 Cr. (Dec 2023) to 0.05 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Mar 2024, the value is -3.18 Cr.. The value appears to be declining and may need further review. It has decreased from -2.80 Cr. (Dec 2023) to -3.18 Cr., marking a decrease of 0.38 Cr..
- For Tax %, as of Mar 2024, the value is 30.19%. The value appears to be increasing, which may not be favorable. It has increased from -0.71% (Dec 2023) to 30.19%, marking an increase of 30.90%.
- For Net Profit, as of Mar 2024, the value is -4.14 Cr.. The value appears to be declining and may need further review. It has decreased from -2.79 Cr. (Dec 2023) to -4.14 Cr., marking a decrease of 1.35 Cr..
- For EPS in Rs, as of Mar 2024, the value is -5.09. The value appears to be declining and may need further review. It has decreased from -3.43 (Dec 2023) to -5.09, marking a decrease of 1.66.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: Unknown
| Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 74.74 | 67.00 | 60.29 | 62.72 | 61.57 | 79.63 | 167.51 | 197.36 | 8.16 | 8.23 | 6.00 | 2.28 |
| Expenses | 68.17 | 60.90 | 53.80 | 56.83 | 56.12 | 74.22 | 160.83 | 191.66 | 6.92 | 7.85 | 5.47 | 8.65 |
| Operating Profit | 6.57 | 6.10 | 6.49 | 5.89 | 5.45 | 5.41 | 6.68 | 5.70 | 1.24 | 0.38 | 0.53 | -6.37 |
| OPM % | 8.79% | 9.10% | 10.76% | 9.39% | 8.85% | 6.79% | 3.99% | 2.89% | 15.20% | 4.62% | 8.83% | -279.39% |
| Other Income | 0.24 | 0.81 | 0.00 | 0.57 | 0.32 | 0.45 | 0.13 | 0.18 | 0.05 | 0.19 | 0.01 | 0.00 |
| Interest | 3.55 | 3.72 | 3.52 | 3.42 | 2.94 | 3.49 | 3.22 | 3.21 | 0.87 | 0.81 | 0.40 | 0.48 |
| Depreciation | 1.40 | 1.51 | 1.64 | 1.65 | 1.70 | 1.69 | 1.75 | 1.96 | 0.29 | 0.29 | 0.25 | 0.23 |
| Profit before tax | 1.86 | 1.68 | 1.33 | 1.39 | 1.13 | 0.68 | 1.84 | 0.71 | 0.13 | -0.53 | -0.11 | -7.08 |
| Tax % | 41.40% | 29.17% | 32.33% | 41.01% | 55.75% | 0.00% | 30.43% | 181.69% | -623.08% | -24.53% | -18.18% | 13.56% |
| Net Profit | 1.09 | 1.19 | 0.90 | 0.83 | 0.50 | 0.68 | 1.28 | -0.56 | 0.95 | -0.40 | -0.09 | -8.04 |
| EPS in Rs | 0.64 | 0.70 | 0.53 | 0.49 | 0.30 | 0.40 | 0.76 | -0.33 | 1.17 | -0.49 | -0.11 | -9.89 |
| Dividend Payout % | 38.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 9.17% | -24.37% | -7.78% | -39.76% | 36.00% | 88.24% | -143.75% | 269.64% | -142.11% | 77.50% | -8833.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | -33.54% | 16.59% | -31.98% | 75.76% | 52.24% | -231.99% | 413.39% | -411.75% | 219.61% | -8910.83% |
Ortin Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: Unknown
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 8.13 | 8.13 | 8.13 | 8.13 |
| Reserves | 3.84 | 5.02 | 5.50 | 6.33 | 6.46 | 7.14 | 8.15 | 6.88 | 3.22 | 2.83 | 2.73 | -5.31 |
| Borrowings | 17.92 | 18.68 | 20.96 | 20.85 | 17.34 | 17.34 | 19.47 | 19.57 | 6.94 | 6.14 | 6.45 | 1.80 |
| Other Liabilities | 34.80 | 31.93 | 23.87 | 21.22 | 20.79 | 32.24 | 60.53 | 73.13 | 2.97 | 3.61 | 3.89 | 1.97 |
| Total Liabilities | 73.50 | 72.57 | 67.27 | 65.34 | 61.53 | 73.66 | 105.09 | 116.52 | 21.26 | 20.71 | 21.20 | 6.59 |
| Fixed Assets | 24.77 | 23.90 | 21.83 | 21.63 | 20.69 | 20.03 | 21.29 | 22.45 | 14.38 | 14.21 | 13.96 | 0.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 | 0.40 | 0.53 | 0.43 | 0.43 | 0.43 | 0.43 | 0.00 |
| Investments | 0.03 | 0.03 | 0.03 | 0.03 | 0.07 | 0.08 | 0.08 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 48.70 | 48.64 | 45.41 | 43.68 | 40.42 | 53.15 | 83.19 | 93.57 | 6.45 | 6.07 | 6.81 | 6.58 |
| Total Assets | 73.50 | 72.57 | 67.27 | 65.34 | 61.53 | 73.66 | 105.09 | 116.52 | 21.26 | 20.71 | 21.20 | 6.59 |
Below is a detailed analysis of the balance sheet data for Ortin Laboratories Ltd based on the most recent figures (Mar 2024) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2024, the value is 8.13 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 8.13 Cr..
- For Reserves, as of Mar 2024, the value is -5.31 Cr.. The value appears to be declining and may need further review. It has decreased from 2.73 Cr. (Mar 2023) to -5.31 Cr., marking a decrease of 8.04 Cr..
- For Borrowings, as of Mar 2024, the value is 1.80 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 6.45 Cr. (Mar 2023) to 1.80 Cr., marking a decrease of 4.65 Cr..
- For Other Liabilities, as of Mar 2024, the value is 1.97 Cr.. The value appears to be improving (decreasing). It has decreased from 3.89 Cr. (Mar 2023) to 1.97 Cr., marking a decrease of 1.92 Cr..
- For Total Liabilities, as of Mar 2024, the value is 6.59 Cr.. The value appears to be improving (decreasing). It has decreased from 21.20 Cr. (Mar 2023) to 6.59 Cr., marking a decrease of 14.61 Cr..
- For Fixed Assets, as of Mar 2024, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 13.96 Cr. (Mar 2023) to 0.01 Cr., marking a decrease of 13.95 Cr..
- For CWIP, as of Mar 2024, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.43 Cr. (Mar 2023) to 0.00 Cr., marking a decrease of 0.43 Cr..
- For Investments, as of Mar 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2024, the value is 6.58 Cr.. The value appears to be declining and may need further review. It has decreased from 6.81 Cr. (Mar 2023) to 6.58 Cr., marking a decrease of 0.23 Cr..
- For Total Assets, as of Mar 2024, the value is 6.59 Cr.. The value appears to be declining and may need further review. It has decreased from 21.20 Cr. (Mar 2023) to 6.59 Cr., marking a decrease of 14.61 Cr..
However, the Borrowings (1.80 Cr.) are higher than the Reserves (-5.31 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -11.35 | -12.58 | -14.47 | -14.96 | -11.89 | -11.93 | -12.79 | -13.87 | -5.70 | -5.76 | -5.92 | -8.17 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
No data available for the Financial Efficiency data table.
No data available for the Shareholding
No data available for the Shareholding Pattern chart.
No data available for the No. of Shareholders chart.
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 12 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | 2.73 |
| Diluted EPS (Rs.) | 2.73 |
| Cash EPS (Rs.) | 3.59 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 14.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 14.47 |
| Revenue From Operations / Share (Rs.) | 50.63 |
| PBDIT / Share (Rs.) | 6.99 |
| PBIT / Share (Rs.) | 6.13 |
| PBT / Share (Rs.) | 4.20 |
| Net Profit / Share (Rs.) | 2.73 |
| NP After MI And SOA / Share (Rs.) | 2.73 |
| PBDIT Margin (%) | 13.81 |
| PBIT Margin (%) | 12.10 |
| PBT Margin (%) | 8.30 |
| Net Profit Margin (%) | 5.38 |
| NP After MI And SOA Margin (%) | 5.38 |
| Return on Networth / Equity (%) | 18.85 |
| Return on Capital Employeed (%) | 34.77 |
| Return On Assets (%) | 5.67 |
| Long Term Debt / Equity (X) | 0.11 |
| Total Debt / Equity (X) | 0.58 |
| Current Ratio (X) | 1.11 |
| Quick Ratio (X) | 0.82 |
| Interest Coverage Ratio (X) | 3.63 |
| Interest Coverage Ratio (Post Tax) (X) | 2.42 |
| Enterprise Value (Cr.) | 62.39 |
| EV / Net Operating Revenue (X) | 0.72 |
| EV / EBITDA (X) | 5.27 |
| MarketCap / Net Operating Revenue (X) | 0.56 |
| Price / BV (X) | 1.97 |
| Price / Net Operating Revenue (X) | 0.56 |
| EarningsYield | 0.09 |
After reviewing the key financial ratios for Ortin Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 12, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 12, the value is 2.73. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 12, the value is 2.73. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 12, the value is 3.59. This value is within the healthy range. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 12, the value is 14.47. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 12, the value is 14.47. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 12, the value is 50.63. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 12, the value is 6.99. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 12, the value is 6.13. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 12, the value is 4.20. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 12, the value is 2.73. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 12, the value is 2.73. This value is within the healthy range. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 12, the value is 13.81. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 12, the value is 12.10. This value is within the healthy range. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 12, the value is 8.30. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 12, the value is 5.38. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 12, the value is 5.38. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 12, the value is 18.85. This value is within the healthy range. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 12, the value is 34.77. This value is within the healthy range. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 12, the value is 5.67. This value is within the healthy range. No previous period data is available for comparison.
- For Long Term Debt / Equity (X), as of Mar 12, the value is 0.11. This value is below the healthy minimum of 0.2. No previous period data is available for comparison.
- For Total Debt / Equity (X), as of Mar 12, the value is 0.58. This value is within the healthy range. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 12, the value is 1.11. This value is below the healthy minimum of 1.5. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 12, the value is 0.82. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 12, the value is 3.63. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 12, the value is 2.42. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 12, the value is 62.39. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 12, the value is 0.72. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 12, the value is 5.27. This value is within the healthy range. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 12, the value is 0.56. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 12, the value is 1.97. This value is within the healthy range. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 12, the value is 0.56. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EarningsYield, as of Mar 12, the value is 0.09. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ortin Laboratories Ltd:
- Net Profit Margin: 5.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 34.77% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 18.85% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.82
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 55.81)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.58
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Mayfair Gardens, 8-2-682/3/A & 3B, Flat no-201, 2nd Floor, Road N Hyderabad Telangana 500034 | info@ortinlabsindia.com www.ortinlabsindia.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Murali Krishna Rayaprolu | Independent Director |
| Mr. S Murali Krishna Murthy | Managing Director |
| Mr. S Srinivas Kumar | Whole Time Director |
| Mr. S Balaji Venkateswarlu | Non Executive Director |
| Mr. B Gopal Reddy | Independent Director |
| Ms. Pottur Sujatha | Independent Director |
| Mr. Pramod Dnyandeo Waghe | Non Executive Director |
| Mr. Shashikant Shankarrao Igave | Non Executive Director |
| Mr. Rutvikbhai Mukeshbhai Beladiya | Additional Director |
| Mrs. Smitaben Suthar | Additional Director |
| Mr. Pratik Bharatbhai Panchal | Additional Director |
| Mr. Ramesh Joshi | Additional Director |
FAQ
What is the intrinsic value of Ortin Laboratories Ltd?
Ortin Laboratories Ltd's intrinsic value (as of 20 July 2025) is 50.12 149.35% higher the current market price of 20.10, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 16.4 Cr. market cap, FY2025-2026 high/low of 26.4/16.2, reserves of -5.31 Cr, and liabilities of 6.59 Cr.
What is the Market Cap of Ortin Laboratories Ltd?
The Market Cap of Ortin Laboratories Ltd is 16.4 Cr..
What is the current Stock Price of Ortin Laboratories Ltd as on 20 July 2025?
The current stock price of Ortin Laboratories Ltd as on 20 July 2025 is 20.1.
What is the High / Low of Ortin Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ortin Laboratories Ltd stocks is ₹26.4/16.2.
What is the Stock P/E of Ortin Laboratories Ltd?
The Stock P/E of Ortin Laboratories Ltd is .
What is the Book Value of Ortin Laboratories Ltd?
The Book Value of Ortin Laboratories Ltd is 3.47.
What is the Dividend Yield of Ortin Laboratories Ltd?
The Dividend Yield of Ortin Laboratories Ltd is 0.00 %.
What is the ROCE of Ortin Laboratories Ltd?
The ROCE of Ortin Laboratories Ltd is 60.2 %.
What is the ROE of Ortin Laboratories Ltd?
The ROE of Ortin Laboratories Ltd is 118 %.
What is the Face Value of Ortin Laboratories Ltd?
The Face Value of Ortin Laboratories Ltd is 10.0.